Pfizer to Focus on Unlocking Value from Acquired Assets and Regaining Momentum at JPM 2024 (With 254-Report Collection)

In theAt the 42nd Annual J.P. Morgan Healthcare Conference (JPM), Pfizer CEO Albert BourlaIndicates,Pfizer had the most successful year in its history. However, this year,Albert Bourla admitted, "Last year was a very bad year for investors." In 2023, Pfizer's stock price fell by 44%.

In terms of vaccines, according to PfizerThe 2023 financial report shows that the revenue of its COVID-19 vaccine Comirnaty plummeted to 11.22 billion US dollars, while the revenue of the RSV vaccine Abrysvo was 890 million US dollars. The RSV vaccines from GSK and Pfizer were successively approved for marketing in May of last year. Although Pfizer is the only RSV vaccine with dual indications for pregnant women and the elderly, its sales are still far behind those of GSK—ArexvySales£12.38 billion(Press1 GBP ≈ 1.2689 USDEquivalent to$1.57 billion。

However,Pfizer expects this year to next yearDuring the RSV high season, approximately 80 million elderly people and 1.5 million pregnant women are suitable for vaccination. The RSV vaccine Abrysvo will provide continuous support to Pfizer's performance throughout the year.BesidesRSV VaccineExternally,Its potential blockbuster products include influenzamRNA Vaccine。Potential Blockbusters Coming to Market After 2030VaccineProduct with Herpes ZostermRNA vaccines, Lyme disease vaccines, etc.

Year-end Benefits：The editor has collected254 copiesParticipating pharmaceutical companies in2024Report materials on JPM, for industry reference,Scan to RegisterThat's all.EmailObtainDownload Address for JPM Learning Materials from 2021 to 2024。

Resource List